L-Nutra Revenue and Competitors

Location

$119M

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • L-Nutra's estimated annual revenue is currently $17M per year.(i)
  • L-Nutra's estimated revenue per employee is $243,000
  • L-Nutra's total funding is $119M.

Employee Data

  • L-Nutra has 70 Employees.(i)
  • L-Nutra grew their employee count by 0% last year.

L-Nutra's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Strategy & Business Development OfficerReveal Email/Phone
3
CIO (Chief Innovation Officer)Reveal Email/Phone
4
VP GrowthReveal Email/Phone
5
Sr. VP, Growth LeaderReveal Email/Phone
6
Head DTC and HCP MarketingReveal Email/Phone
7
Head Technology and MarketingReveal Email/Phone
8
VP Product DevelopmentReveal Email/Phone
9
Director CommunicationsReveal Email/Phone
10
Director Customer Service & ExcellenceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$16.8M6917%N/AN/A
#2
$177.5M526-1%N/AN/A
#3
$7.3M3413%N/AN/A
#4
$12.9M5528%$25.9MN/A
#5
$4.7M25-11%N/AN/A
#6
$14.8M6120%N/AN/A
#7
$13.6M560%N/AN/A
#8
$5.3M28-7%N/AN/A
#9
$23.2M8616%N/AN/A
#10
$13.9M572%N/AN/A
Add Company

What Is L-Nutra?

L-Nutra is the leading nutritechnology company, developing innovative Fasting Mimicking Diets (FMD) that can be consumed for a predetermined number of consecutive days, with the frequency dependent on the condition and patient. FMDs nourish the body while keeping it in a fasting mode, which promotes positive long-term effects on biological aging, health and a variety of other factors, such as weight, abdominal fat , and maintaining healthy levels of glucose, cholesterol, blood pressure, and other key health factors. L-Nutra's first generation of FMDs includes ProLon® and Chemolieve®. ProLon is a 5-day FMD aimed at promoting longevity, managing body weight, and improving health by supporting cellular protection, multi-system regeneration and rejuvenation. ProLon launched in the United States in 2016. Chemolieve is a 4-day FMD being studied for use with oncology patients to protect the normal cells of the body and decrease side effects of chemotherapy without interfering with its efficacy.

keywords:N/A

$119M

Total Funding

70

Number of Employees

$17M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

L-Nutra News

2022-04-17 - L-Nutra Reports Initial Data Showing Improvements in ...

D., CEO and Chairman of L-Nutra Inc. Obesity and metabolic dysfunction have long been linked to increased prostate cancer mortality and overall...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.1M70-8%N/A
#2
$3.5M700%$7.5M
#3
$9.1M7059%N/A
#4
$13.2M70N/AN/A
#5
$15.8M70N/AN/A